Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) released its quarterly earnings data on Monday. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.44) by $0.02, FiscalAI reports.
Acrivon Therapeutics Price Performance
Shares of ACRV stock opened at $1.46 on Tuesday. The firm has a market cap of $62.56 million, a P/E ratio of -0.78 and a beta of 1.96. Acrivon Therapeutics has a 1-year low of $1.27 and a 1-year high of $3.56. The firm has a fifty day moving average of $1.82 and a two-hundred day moving average of $1.74.
Insider Activity at Acrivon Therapeutics
In related news, CEO Peter Blume-Jensen sold 14,036 shares of Acrivon Therapeutics stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $2.21, for a total value of $31,019.56. Following the completion of the transaction, the chief executive officer directly owned 2,230,052 shares in the company, valued at approximately $4,928,414.92. This trade represents a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 14,843 shares of company stock worth $32,549 over the last quarter. Company insiders own 10.50% of the company’s stock.
Analysts Set New Price Targets
Get Our Latest Analysis on Acrivon Therapeutics
Acrivon Therapeutics Company Profile
Acrivon Therapeutics is a clinical-stage biopharmaceutical company developing precision medicines for cancer. Its research focuses on identifying treatments for patients whose tumors have molecular characteristics that may make them more likely to respond to a particular therapy. The company’s Acrivon Predictive Precision Proteomics (AP3) platform analyzes protein activity in tumor samples to identify these characteristics and help guide patient selection. Acrivon’s clinical-stage candidate ACR-368 is a small-molecule inhibitor of the CHK1 and CHK2 enzymes being studied in solid tumors.
Recommended Stories
- Five stocks we like better than Acrivon Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
